Ranbaxy Company Profile
 
 Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international

pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence all the top 25 pharmaceutical markets of the world. The company has a global footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over 150 countries. 
 
 In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing. 
 
 Ranbaxy was incorporated in 1961 and went public in 1973. Mission
 
 Ranbaxy's mission is 'Enriching lives globally, with quality and affordable pharmaceuticals'. 
 
 Values  Achieving customer satisfaction is fundamental to our business.  Provide products and services of the highest quality.  Practice dignity and equity in relationship and provide opportunities for our people to realize their full potential.  Ensure profitable growth and enhance wealth of the shareholders.  Foster mutually beneficial relations with all our business partners.  Manage our operations with high concern for safety and environment.  Be responsible corporate citizen.

Financials

To have quality as the key in all processes and is the determining factor that kindles the belief patients have in their medicines and ultimately our business. It aims to make high quality medicines accessible and affordable to people around the world. Environment. Ranbaxy and Daiichi Sankyo have started mobile healthcare clinics in India. 6. trust and integrity. Ranbaxy‟s new Management Team and Daiichi Sankyo are committed to the utmost levels of professionalism and integrity.3 Bn. the community at large. 2. It is also clearly reflected and well defined into Ranbaxy‟s value statements of “Managing our operations with high concern for safety and environment” and “Be a responsible corporate citizen”. Health and Safety Ranbaxy is fully committed to achieve Environment. They aim to ensure that all Ranbaxy facilities continue to meet the high standards that are expected from a global pharmaceutical company. and the environment including the natural . 3. driven by harmony. It aims to progress towards a new culture that is open and transparent. Thinking and working responsibly so that the employees. 5. Health & Safety (EHS) excellence and conduct its activities in the most responsible manner.
 
 For the year 2012. These mobile healthcare clinics will provide greater access to medical and primary healthcare and save many lives in areas that lack basic healthcare. The company has a balanced mix of revenues from emerging and developed markets that contribute 41% and 51% respectively. To be a leader in the Pharmaceutical industry and to be a profitable company with a steady growth in earnings. It aims to promote self-governance at all levels by introducing a Whistle Blower Policy . To improve access to medical services. Over the years. importance of EHS has been stressed and extensively promoted as a corporate culture within Ranbaxy. 8. the company recorded Global Sales of US $ 2. The aim is to reduce child mortality and improve maternal health. 4.an extension of Ranbaxy‟s existing „Code of Conduct‟. 7. 
 Objectives: 1.

Cipla also has an export market and regularly exports to more than 185 countries in all corners of the world. respiratory disease and cancer. are protected leaving minimal environmental footprints. Cipla makes drugs to treat cardiovascular disease. and that for over 75 years. regardless of their economic circumstances or where in the world they happen to live. They‟ll continue to bring a smile on as many faces as we can to . probably bestknown outside its home country for pioneering the manufacture of lowcost anti-AIDS drugs for HIV-positive patients in developing countries. And along the way realised. engineering. and plant supply. Cipla cooperates with other enterprises in areas such as consulting. Cipla Company Profile
 
 Cipla Limited is an Indian pharmaceutical company. The company has become well-known internationally for its dedication to working according to these values and prioritizing a socially-conscious approach to its operations. depression and many other health conditions. weight control. VISION Cipla started with a vision to build a healthy India. It has played a similarly prominent role in expanding access to drugs to fight influenza. Ranbaxy has adopted a top down approach and embraced the principles and codes of best EHS practices into its redefined world class EHS Management System. know-how transfer. Industrial & Pharmaceutical Laboratories in 1935. is integral to Ranbaxy‟s EHS philosophy. Cipla has always emphasized self-reliance and the right of all people to health and access to medicine. commissioning. Founded by nationalist Indian scientist Khwaja Abdul Hamied as The Chemical. they could contribute to making the world a healthier place.resources. On the road to EHS excellence. and its products are distributed in virtually every country of the world. project appraisal. arthritis. quality control. diabetes. support. that in their own small way. Cipla received the Thomson Reuters India Innovation Award in 2012 Founded prior to Indian independence by Khwaja Abdul Hamied on the principle that India needed to become self-sufficient in supplying medicine to its people. Apart from its presence in the Indian market.

In addition. available at affordable prices. etc. .heal the world as much as we can. aged patients in slums and villages through non-profit organizations. thus making world-class medicines accessible to patients in India. • The Cipla Palliative Care and Training Centre in Pune continues to provide holistic care to terminally ill cancer patients and their families free of charge.700 patients. a Pune-based organization which runs a home for children with HIV infection. by providing healthcare education. Manavya operates a mobile dispensary in villages on the outskirts of Pune and it is fully funded by the company. • In a humanitarian effort to support cancer patients and relieve their burden. HIV/AIDS and several neglected diseases. We work closely with several reputed non-profit organizations such as Drugs for Neglected Diseases Initiative. • On the occasion of Cipla‟s Platinum Jubilee in 2010. Corporate Social Responsibility Being a good corporate citizen is an integral part of our core value caring for life. we made a breakthrough in reducing the prices of cancer drugs. We also provide medicines to treat over a million poor. scholarships. we support several health. 5 crore. we set up the Cipla Foundation by contributing a sum of Rs. comfort and solace to more than 7. • We extend support to Manavya. Till now the Centre has given treatment. This is part of our commitment to improve the quality of life for these communities. improvement of community infrastructure. The Foundation aims to provide care and financial support to people in need of healthcare and education in India. The focus of the Cipla Palliative Care Centre is to reach out to more cancer patients who need Palliative Care and to integrate Palliative medicine with curative therapy. Medecins Sans Frontieres and the Clinton Foundation in order to make drugs for malaria. both directly and through our Charitable Trusts. Because there‟ll always be a better world out there for those who have the passion to create it. educational and welfare activities in communities surrounding the company‟s factories.

Have the Fund recommend relaxing international restrictions on patent infringement. Strengths:  Our drugs have certified quality and low price. Weaknesses:  Stress between our goal of profitability and our desire to be seen as humanitarian  Legal freedom to produce generics expires in 2005. Shed our image as technology pirates. 2. Enhance our Reputation: Let the world see us as a for-profit corporation with humanitarian interests.Objectives: 1. not patented originals.  Treatment prevents the global spread of opportunistic diseases. Continued Profit from our generic drug activities. for the treatment of AIDS. Catastrophic levels of HIV would affect our employment base and could indirectly damage almost any of our business activities and the world economy.  Providing drug meets actual emergent demand as opposed to curving behavior which is unpopular. . Emphasizes Distribution: Have the Global Fund focus on developing the distribution networks and infrastructure for antiAIDS medicines. etc. 3. Maintain the general public health of India and the world: A severe epidemic must be avoided in India and minimized in other regions. It also reduces transmission of both mother to child and people who don‟t know that they are infected. Doctors Without Borders. Increase Usage and Production of Generic Drugs: Encourage the Fund to rely on generic drugs. 2.  Humanitarian image  Medical treatment is more predictable and inspires hope that leads to prevention.  Probable opposition from patent-holding drug companies. Increase Donations to the Fund from Rich Countries: Fund must be able to afford our products Interests: 1. This makes them attractive to international organizations such as UNAIDS. 3.

Costs:  By emphasizing treatment over prevention. Treatment may be less cost-effective than prevention. Policies:  Increase focus on treatment of HIV/AIDS patients.  Continued patent infringement might hurt the long-term development of new drugs.  Have the Fund invest in an improved distribution infrastructure in Africa and other epidemic regions. we risk an accelerated spread of the epidemic. .  Distribution systems require a lot of capital and human resources.  The development of distribution system has positive externality because it can be applied to other diseases. Benefits:  The possibility exists of giving a vast number of patients in developing countries access to cutting edge anti-AIDS medicines.  Treatment encourages prevention.  Increase financial obligation of rich countries.